Lipidology is a medical subspecialty focused on diagnosing and treating disorders of blood fats, including cholesterol, triglycerides, and other particles that circulate in your bloodstream. While most people associate it with “high cholesterol,” the field goes considerably deeper, covering genetic conditions, advanced risk assessment, and a growing toolkit of therapies that didn’t exist a decade ago.
The specialty sits at the intersection of cardiology, endocrinology, internal medicine, and even pediatrics and obstetrics. A lipidologist is a physician who has developed focused expertise in how your body produces, transports, and clears fatty particles from the blood, and what happens when those processes go wrong.
What Lipidologists Actually Do
A standard cholesterol check at your annual physical gives you four numbers: total cholesterol, LDL (“bad”) cholesterol, HDL (“good”) cholesterol, and triglycerides. A lipidologist interprets those numbers in context but also looks well beyond them. Advanced biomarkers like apolipoprotein B (ApoB) and lipoprotein(a), often written as Lp(a), can reveal cardiovascular risk that a basic panel misses entirely.
ApoB is a protein found on every particle capable of building up plaque in your arteries. Because there’s exactly one ApoB molecule per particle, measuring it gives a direct count of how many dangerous particles are circulating. A large international study called INTERHEART found that ApoB levels were a better predictor of heart attack than total cholesterol, LDL cholesterol, or non-HDL cholesterol. That finding has been confirmed across dozens of subsequent studies. Lp(a) is a genetically determined particle that independently raises your risk for heart disease, and roughly one in five people has elevated levels without knowing it.
Risk assessment is another core function. The ACC/AHA Pooled Cohort Equation, used in the widely available ASCVD Risk Estimator, calculates your 10-year probability of a heart attack or stroke based on age, blood pressure, cholesterol, diabetes status, and smoking history. It covers adults 40 to 79. A separate lifetime risk calculator extends to people as young as 20. A lipidologist uses these tools alongside advanced biomarkers, imaging results, and family history to build a more complete picture of your cardiovascular future than any single test can provide.
Conditions That Bring People to a Lipidologist
The most common reason for a referral is cholesterol that won’t budge despite standard treatment, or side effects that make standard treatment intolerable. But the full list is broader than most people expect. Johns Hopkins’ lipid program, one of the most established in the country, treats patients with:
- Familial hypercholesterolemia (FH), a genetic condition that causes dangerously high LDL from birth
- Familial combined hyperlipidemia, which elevates both cholesterol and triglycerides
- High lipoprotein(a), a genetically driven risk factor with no response to diet or statins
- Statin intolerance, or LDL that remains above goal despite maximum statin therapy
- Severe hypertriglyceridemia, which can trigger pancreatitis when levels climb high enough
- Familial chylomicronemia syndrome, a rare condition where the body cannot clear dietary fat from the blood
- Lipid disorders tied to kidney or liver disease
FH deserves special attention because it’s both common and dramatically underdiagnosed. About 1 in 250 people carry a gene variant that roughly doubles their LDL cholesterol from birth. Without treatment, many develop heart disease in their 30s or 40s. An expert panel from the American College of Cardiology has recommended that genetic testing for FH become the standard of care for anyone with a definite or probable clinical diagnosis, as well as for their at-risk family members. The clinical clues include very high LDL (typically above 190 mg/dL in adults), a family history of early heart attacks, and physical signs like cholesterol deposits in the tendons or a whitish ring around the iris.
How Lipid Disorders Are Treated
Statins remain the foundation. Drugs like atorvastatin and rosuvastatin are the most widely prescribed, and their use continues to grow. They work by slowing cholesterol production in the liver, which forces liver cells to pull more LDL out of the bloodstream. For many people, a statin alone brings LDL to a safe range.
When it doesn’t, or when side effects make full-dose statins impractical, lipidologists layer on additional therapies. Ezetimibe blocks cholesterol absorption in the gut and is often the first add-on. Bempedoic acid targets the same cholesterol production pathway as statins but acts at an earlier step, which appears to avoid the muscle pain some people experience with statins.
The biggest shift in recent years has been the arrival of PCSK9 inhibitors. PCSK9 is a protein your liver makes that breaks down the receptors responsible for clearing LDL from your blood. Blocking that protein means more receptors stay active and more LDL gets removed. Two injectable antibodies (alirocumab and evolocumab) are given every two weeks or monthly. A newer option, inclisiran, uses a small interfering RNA molecule to stop the liver from producing PCSK9 in the first place, and it only needs to be injected twice a year after an initial dose. These therapies can cut LDL by 50 to 60 percent on top of whatever a statin achieves, which makes previously unreachable targets possible for high-risk patients.
Current European guidelines recommend PCSK9 inhibitors specifically for patients at very high cardiovascular risk whose LDL stays elevated despite the highest tolerable statin dose plus ezetimibe. American expert consensus takes a similar position, emphasizing that these newer agents should supplement statins rather than replace them.
Beyond LDL: Triglycerides and Residual Risk
Some patients reach their LDL goal and still face elevated risk because of high triglycerides or elevated ApoB. Measuring ApoB is particularly useful in people with high triglycerides because it reveals whether those triglyceride-rich particles are the dangerous, artery-clogging type. In these patients, both ApoB and non-HDL cholesterol are recommended as part of routine evaluation.
Newer research is targeting proteins that regulate triglyceride metabolism. One protein called ANGPTL3 helps control how your body breaks down blood fats. An investigational drug called zodasiran silences the gene that produces ANGPTL3 in the liver, leading to significant drops in triglycerides, LDL, and ApoB in early clinical trials. It has shown particular promise for people with homozygous familial hypercholesterolemia, the most severe form of genetic high cholesterol, where standard treatments often fall short because the LDL receptors themselves are defective.
How Lipidologists Are Trained
Lipidology draws physicians from multiple backgrounds. Some start in cardiology, others in endocrinology, internal medicine, family medicine, or preventive medicine. The American Board of Clinical Lipidology offers a certification exam that requires a current medical license and either two years of clinical lipid experience or board certification in another specialty. Certification is renewed every 10 years.
The field has been pushing for formal recognition as a distinct subspecialty, arguing that the complexity of genetic lipid disorders, advanced diagnostics, and rapidly evolving therapies has outgrown what general training in any single parent specialty covers. A 2024 position paper in the Journal of Clinical Lipidology made the case that lipidology’s scope, spanning rare storage diseases, lipoprotein metabolism, and multi-organ genetic conditions, is unique enough to warrant standalone specialty status.
When a Lipidologist Adds Value
Most people with mildly elevated cholesterol will never need a lipidologist. Your primary care doctor can manage a straightforward case with lifestyle changes and a statin. A lipidologist becomes valuable when the situation gets complicated: your LDL is extremely high and you have a family history of early heart disease, suggesting a genetic cause. You’ve tried multiple statins and can’t tolerate any of them. Your triglycerides spike above 500 mg/dL, putting you at risk for pancreatitis. Your Lp(a) comes back elevated and you want to understand what that means for your long-term risk. Or you’re already on maximum therapy and your numbers still aren’t where they need to be.
In these scenarios, a lipidologist brings deeper familiarity with advanced biomarkers, genetic testing, and the newer drug classes that many general practitioners haven’t yet incorporated into routine practice. The goal is the same one that drives all of lipidology: keeping fatty particles from quietly building up in your artery walls for years before they cause a heart attack or stroke.